MIT Holding today reported the intake of patients for a U.S. FDA clinical trial. MIT Holding, through its affiliates, is acting as sub-investigators for Melinta Theraputics, the primary investigator in the study managed by SERRG Savannah. MIT Holding will generate revenues throughout this 12-month study.
Walter Drakeford, president of MIT Holding stated, “We are pleased to open this new revenue stream as a result of being selected by SERRG as a sub-investigator facility. This is evidence that our corporate re-organization and business model is capable of opening and generating new income streams through our partner affiliation programs. The facility and staff underwent intense scrutiny and was selected after a rigorous evaluation by SERRG and the State of GA. The company is excited to continue pursuing other similar opportunities in this lucrative and specialized field.”
Patients will receive a two- to four-hour infusion in a blind study. The trial will last for twelve months with approximately 666 patients treated in the entire trial at multiple facilities throughout the United States, under various sub-investigators.
For more information visit www.mitholdingsinc.com
Let us hear your thoughts: MIT Holding, Inc. Message Board